Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Abhijit Ramachandran"'
Autor:
Madhura Joglekar-Javadekar, Steven Van Laere, Michael Bourne, Manal Moalwi, Pascal Finetti, Peter B. Vermeulen, Daniel Birnbaum, Luc Y. Dirix, Naoto Ueno, Monique Carter, Justin Rains, Abhijit Ramachandran, Francois Bertucci, Kenneth L. van Golen
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 7, Pp 564-573 (2017)
PURPOSE: Inflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer due to its rapid onset and highly invasive nature. IBC carries 5- and 10-year disease-free survival rates of ~45% and
Externí odkaz:
https://doaj.org/article/75c90e96945a459bb985cf9daa5b60e4
Autor:
Michael Andreeff, Abhijit Ramachandran, Farhad Ravandi, Jorge E. Cortes, Gautam Borthakur, Rodrigo O. Jacamo, Ye Chen, Marina Konopleva, Chen Gao, Weiguo Zhang
PDF file - 468K, S1. Sorafenib-resistant murine AML (Ba/F3-ITD-Res) and parental cells (Ba/F3-ITD) were treated with indicated concentrations of sorafenib for 72 hours. Cell apoptosis induction was analyzed by measuring the percentage of annexin V-po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f6a89b4cc7d99af36533512bc32e7a0
https://doi.org/10.1158/1078-0432.22449978.v1
https://doi.org/10.1158/1078-0432.22449978.v1
Autor:
Michael Andreeff, Abhijit Ramachandran, Farhad Ravandi, Jorge E. Cortes, Gautam Borthakur, Rodrigo O. Jacamo, Ye Chen, Marina Konopleva, Chen Gao, Weiguo Zhang
Purpose: FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (FLT3-ITD) mutations are common in patients with acute myeloid leukemia (AML). These patients regularly develop resistance to FLT3 inhibitors suggesting that targeted combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::686167c5b8edd2121b1ece035c8e1bc9
https://doi.org/10.1158/1078-0432.c.6521811
https://doi.org/10.1158/1078-0432.c.6521811
Autor:
Kenneth L. van Golen, Steven Van Laere, Daniel Birnbaum, Abhijit Ramachandran, Madhura Joglekar-Javadekar, Justin Rains, Monique Carter, Pascal Finetti, François Bertucci, Manal Moalwi, Luc Dirix, Naoto T. Ueno, Peter B. Vermeulen, Michael Bourne
Publikováno v:
Neoplasia
Neoplasia, 2017, 19 (7), pp.564-573. ⟨10.1016/j.neo.2017.03.002⟩
Neoplasia, Elsevier, 2017, 19 (7), pp.564-573. ⟨10.1016/j.neo.2017.03.002⟩
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 7, Pp 564-573 (2017)
Neoplasia, 2017, 19 (7), pp.564-573. ⟨10.1016/j.neo.2017.03.002⟩
Neoplasia, Elsevier, 2017, 19 (7), pp.564-573. ⟨10.1016/j.neo.2017.03.002⟩
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 7, Pp 564-573 (2017)
International audience; PURPOSE: Inflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer due to its rapid onset and highly invasive nature. IBC carries 5-and 10-year disease-free survival rates of ~45% and b20%, respectively.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c52791f612d4a17e2c3a1b95a2856c44
https://hal.science/hal-01789694/file/Joglekar-Javadekar_Neoplasia_2017.pdf
https://hal.science/hal-01789694/file/Joglekar-Javadekar_Neoplasia_2017.pdf
Autor:
Marina Konopleva, Gautam Borthakur, Ye Chen, Jorge E. Cortes, Farhad Ravandi, Weiguo Zhang, Chen Gao, Michael Andreeff, Abhijit Ramachandran, Rodrigo Jacamo
Publikováno v:
Clinical Cancer Research. 20:2363-2374
Purpose: FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (FLT3-ITD) mutations are common in patients with acute myeloid leukemia (AML). These patients regularly develop resistance to FLT3 inhibitors suggesting that targeted combination
Autor:
Allison Galanis, Mark J. Levis, Hayley S Ma, Donald Small, Trivikram Rajkhowa, Abhijit Ramachandran, Jorge E. Cortes
Publikováno v:
Blood. 123:94-100
Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating mutations an attractive drug target because they are probable dri
Autor:
Michael S, Roberts, David C, Turner, Thandranese S, Owens, Abhijit, Ramachandran, Cynthia, Wetmore, Stacy L, Throm, Clinton F, Stewart
Publikováno v:
Journal of Chromatography B. 929:1-5
A LC-ESI-MS/MS method for the determination of crenolanib (CP-868,596) in human serum was developed and validated employing d4-CP-868,596 as an internal standard (ISTD). In addition to human serum, the method was also partially validated for crenolan
Autor:
Diana J. Griffith, Janice Patterson, Abhijit Ramachandran, Arin McKinley, Maria Debiec-Rychter, Ajia Presnell, Michael Heinrich
Publikováno v:
Clinical Cancer Research. 18:4375-4384
Purpose: To determine the potential of crenolanib, a potent inhibitor of PDGFRA, to treat malignancies driven by mutant PDGFRA. Experimental Design: The biochemical activity of crenolanib was compared with imatinib using a panel of PDGFRA-mutant kina
Publikováno v:
The Journal of Physical Chemistry B. 115:6138-6148
Solid-state nanopores provide a direct means to detect and analyze DNA and proteins. In a typical setup, the DNA molecules travel through a nanopore under electrophoretic voltage bias. The nanopore is sandwiched between two chambers that are filled w
Publikováno v:
American Journal of Biomedical Sciences. :344-351
A major challenge in using solid-state nanopores for DNA detection and sequencing is the molecular selectivity and sensitivity resolution through proper control of DNA-nanopore interface. This paper explores the interaction mechanisms between DNA and